Oportuzumab monatox clinical trials
Also written Vicinium, Proxinium and VB4-845.
How each study uses Oportuzumab monatox is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2015 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Sesen Bio, Inc. (4) · Qilu Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses Oportuzumab monatox is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCGCompletedPhase 3Sesen Bio, Inc.NCT02449239Written as Vicinium
- Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder CancerStatus unknownPhase 3Qilu Pharmaceutical Co., Ltd.NCT04859751Written as VB4-845 Injection
- Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In SituCompletedPhase 2Sesen Bio, Inc.NCT00462488Written as Vicinium
- Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck CancerTerminatedPhase 2/3Sesen Bio, Inc.NCT00412776Written as Proxinium
- Study of Proxinium for Treating Patients With Squamous Cell Head and Neck CancerTerminatedPhase 2Sesen Bio, Inc.NCT00272181Written as Proxinium
Codes
What other systems call Oportuzumab monatox · ClinicalTrials.gg INT005515
- UNII (FDA) 945CY7ZMI2OPORTUZUMAB MONATOXConfirmed FDA, Wikidata
- Wikidata Q3884218Oportuzumab monatoxConfirmed FDA, Wikidata
- NCI Thesaurus C61307Oportuzumab MonatoxOne source FDA
- DrugBank DB05319One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 945CY7ZMI2 | OPORTUZUMAB MONATOX | Confirmed FDA, Wikidata |
| Wikidata | Q3884218 | Oportuzumab monatox | Confirmed FDA, Wikidata |
| NCI Thesaurus | C61307 | Oportuzumab Monatox | One source FDA |
| DrugBank | DB05319 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.